Poziotinib has been shown to target EGFR ex20-ins in certain tumor types, however, a phase II study of poziotinib in adult patients with EGFR or HER2 activating mutations in advanced malignancies (NCT04172597) and which included a glioblastoma arm, was prematurely discontinued by the sponsor (according to the clinicaltrials.gov website as a ‘strategic business decision unrelated to safety)’, and likely due to rarity of the populations under study. This evidence concerns the gene EGFR and glioblastoma.